At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Gemcitabine and oxaliplatin (GemOx) is a standard chemotherapy combination used to treat a cancer of the bile ducts called cholangiocarcinoma. In this study, researchers want to see if adding another treatment that is delivered by a pump device (hepatic arterial infusion or HAI) to GemOx therapy is more effective than GemOx alone for patients with previously untreated inoperable cholangiocarcinoma. The HAI pump, which is implanted in the abdomen during a surgical procedure, continuously delivers the drugs floxuridine and dexamethasone directly to the liver.
-
Researchers want to learn if AMG 193 in combination with standard treatment is safe for people with advanced pancreatic cancer. The people in this study have pancreatic ductal adenocarcinoma (PDAC) that has metastasized (spread). In addition, their cancers have a mutation (change) in the MTAP gene. This results in a lack of the MTAP protein, which may help cancer grow.
-
However, SBRT may not be enough for people with intermediate-risk prostate cancer and unfavorable genetic features. These features may make it more likely that the cancer will come back after radiation therapy. These people may benefit from SBRT with hormonal therapy early in their care.
-
Researchers want to find the best dose of ZL-1310 to use in people with advanced digestive tumors. The people in this study have gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) that spread and keeps growing after treatment. These tumors include NEC of the esophagus, stomach, pancreas, gallbladder, or colon/rectum.
- A Phase 1 Study of LY4170156 in People With Solid Tumors
Full Title A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody- Drug Conjugate Targeting Folate Receptor alpha-Expressing Tumor Cells, in Participants with Selected Advanced Solid Tumors
Purpose
Researchers want to find the best dose of LY4170156 to treat people with solid tumors. The people in this study have solid tumors that keep growing even after treatment. Their tumors also make a protein called FRA, which plays a role in cancer growth. The tumors treated in this study include:
- Breast cancer
- Ovarian cancer
- Cervical cancer
- Endometrial cancer
- Colorectal cancer
- Non-small cell lung cancer
- Pancreatic cancer
LY4170156 is a type of drug called an antibody-drug conjugate (ADC). ADCs are made up of an antibody linked to a drug. The antibody binds to a cancer cell, and the drug enters the cell and kill it.
LY4170156 targets cells that make FRA. By destroying these cells, LY4170156 may help slow or stop the growth of your cancer. It is given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have a solid tumor that keeps growing or came back after treatment.
- Have recovered from the serious side effects of prior therapies before getting LY4170156.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information and to see if you can join this study, please call 646-888-4226.
Protocol
24-195Phase
Phase I (phase 1)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06400472ClinicalTrials.gov
- A Phase 1 Study of NT-175 in People With Advanced Solid Tumors
Full Title An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects with Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation
Purpose
Researchers want to find the best dose of NT-175 in people with advanced solid tumors. The people in this study have cancers that are inoperable (cannot be surgically removed) or metastatic (have spread). The types of tumors include:
- Non-small cell lung cancer
- Colorectal cancer
- Head and neck squamous cell carcinoma
- Pancreatic cancer
- Ovarian cancer
- Breast cancer
In addition, the cancers have a mutation (change) in the TP53 R175H gene. The study participants also have a molecule called HLA-A*02:01 on their cells.
NT-175 is made in a laboratory using your collected white blood cells (T cells). The T cells in NT-175 have been genetically changed so they target cells with mutated TP53 R175H. NT-175 is given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have an inoperable or metastatic solid tumor with a mutated TP53 R175H gene.
- Be positive for HLA-A*02:01.
- Have cancer that keeps growing after treatment.
- Have completed prior anti-cancer therapy at least 2 weeks before getting NT-175.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Adam Schoenfeld’s office at 646-608-2091.
Protocol
25-078Phase
Phase I (phase 1)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05877599ClinicalTrials.gov
-
Researchers are assessing a new combination therapy for neuroblastoma that has a high chance of coming back after treatment. This study is for children with high-risk neuroblastoma who have not gotten more than 1 chemotherapy cycle.
-
Researchers want to find the best dose of INCB160058 to treat myeloproliferative neoplasms such as myelofibrosis. The people in this study have myeloproliferative neoplasms that came back or keep growing even after treatment. In addition, their cancers have a mutation (change) in the JAK2 gene.
-
Researchers are expanding access to the drug zidesamtinib for people with advanced solid tumors. The people in this study have non-small cell lung cancer (NSCLC) or another solid tumor with a fusion (change) in the ROS1 gene. This fusion can cause cancer cells to multiply and spread.
-
Researchers want to find the best dose of REM-422 to use in people with advanced adenoid cystic cancer (ACC). ACC most commonly starts in the salivary glands. The people in this study have ACC that has spread and may high levels of a protein called MYB. This protein can cause cancer cells to grow.